• Kymera Therapeutics named Elizabeth Laws as senior vice president, global program team leader for KT-621, its oral STAT6 degrader.
• Laws previously served as senior vice president, head of Sanofi Integrated Launch & Commercialization Excellence.
• She earlier led Sanofi’s immunology and inflammation therapeutic area, including global development strategy for Dupilumab/Dupixent.
• Kymera expects Phase 2b atopic dermatitis data by year-end 2026; Phase 2b asthma data targeted for late 2027.
• Phase 3 atopic dermatitis trials planned to start by mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070700PRIMZONEFULLFEED9757731) on July 07, 2026, and is solely responsible for the information contained therein.